Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Demographic and clinical data of rheumatoid arthritis patients at entry of study

From: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Parameter Respondersa Non-responders
  Subset 1b (n = 6) Subset 2 (n = 10) Subset 1 (n = 7) Subset 2 (n = 10)
Age (years) 54.1 ± 13.8c 55.2 ± 9.2 56.1 ± 11.7 58.9 ± 11.6
Sex (men/women) 1/5 2/8 1/6 4/6
RA duration (years) 11.7 ± 8.0 11.1 ± 7.3 12 ± 10.2 10.5 ± 5.3
Methotrexate (mg/week)d 12.5 ± 5.5 13 ± 2.8 15.4 ± 2.7e 11.5 ± 3.2
Prednisone (mg/day) 12.1 ± 5.6 8.5 ± 4.2 10.3 ± 8.7 8.2 ± 5.4
Patients with NSAIDs 3 6 5 4
Patients with rheumatoid factor 4 8 5 6
Patients with anti-CCP absg 3 8 5 8
  1. aCategorised as indicated in Materials and methods. bTranscript levels were measured by microarray analysis for subset 1 or qRT-PCR for subset 2. cMean ± standard deviation. dMaximally tolerated dose in a given patient. eSignificant difference between subsets 1 and 2 within non-responders (p < 0.05, Mann and Whitney's non-parametric test). In this table, all other comparisons were non-significant. Anti-CCP abs, anti-cyclic citrullinated peptide antibodies; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis.